|
Célula vcanbio & Gene Engineering Corp., Ltd (600645.SS) Valoración de DCF
CN | Healthcare | Biotechnology | SHH
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS) Bundle
Independientemente de si es un inversor o un analista, esta calculadora DCF (600645SS) es su recurso de referencia para una valoración precisa. Cargado con datos reales de la celda VCANBIO & Gene Engineering Corp., Ltd, puede modificar pronósticos y observar los efectos en tiempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,386.8 | 1,318.9 | 1,535.3 | 1,554.9 | 1,589.7 | 1,649.5 | 1,711.4 | 1,775.7 | 1,842.5 | 1,911.7 |
| Revenue Growth, % | 0 | -4.9 | 16.41 | 1.27 | 2.24 | 3.76 | 3.76 | 3.76 | 3.76 | 3.76 |
| EBITDA | 277.1 | 53.8 | 358.7 | 321.2 | 277.1 | 282.1 | 292.7 | 303.7 | 315.1 | 327.0 |
| EBITDA, % | 19.98 | 4.08 | 23.37 | 20.66 | 17.43 | 17.1 | 17.1 | 17.1 | 17.1 | 17.1 |
| Depreciation | 118.6 | 127.6 | 140.4 | 153.9 | 143.6 | 152.8 | 158.5 | 164.5 | 170.6 | 177.1 |
| Depreciation, % | 8.55 | 9.68 | 9.15 | 9.9 | 9.03 | 9.26 | 9.26 | 9.26 | 9.26 | 9.26 |
| EBIT | 158.5 | -73.9 | 218.3 | 167.3 | 133.5 | 129.3 | 134.2 | 139.2 | 144.5 | 149.9 |
| EBIT, % | 11.43 | -5.6 | 14.22 | 10.76 | 8.4 | 7.84 | 7.84 | 7.84 | 7.84 | 7.84 |
| Total Cash | 1,033.4 | 1,060.3 | 1,195.7 | 1,393.4 | 1,581.2 | 1,391.7 | 1,444.0 | 1,498.3 | 1,554.6 | 1,613.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 555.6 | 512.6 | 510.9 | 576.0 | 610.5 | 619.1 | 642.3 | 666.5 | 691.5 | 717.5 |
| Account Receivables, % | 40.06 | 38.87 | 33.28 | 37.04 | 38.41 | 37.53 | 37.53 | 37.53 | 37.53 | 37.53 |
| Inventories | 218.9 | 222.4 | 227.0 | 248.1 | 247.9 | 260.5 | 270.3 | 280.5 | 291.0 | 302.0 |
| Inventories, % | 15.78 | 16.86 | 14.78 | 15.96 | 15.59 | 15.8 | 15.8 | 15.8 | 15.8 | 15.8 |
| Accounts Payable | 73.1 | 81.4 | 69.7 | 105.1 | 103.4 | 96.5 | 100.1 | 103.9 | 107.8 | 111.8 |
| Accounts Payable, % | 5.27 | 6.18 | 4.54 | 6.76 | 6.5 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 |
| Capital Expenditure | -123.0 | -91.7 | -127.7 | -99.2 | -88.6 | -119.1 | -123.5 | -128.2 | -133.0 | -138.0 |
| Capital Expenditure, % | -8.87 | -6.95 | -8.32 | -6.38 | -5.57 | -7.22 | -7.22 | -7.22 | -7.22 | -7.22 |
| Tax Rate, % | 19.71 | 19.71 | 19.71 | 19.71 | 19.71 | 19.71 | 19.71 | 19.71 | 19.71 | 19.71 |
| EBITAT | 69.4 | -105.2 | 152.1 | 121.8 | 107.2 | 94.8 | 98.4 | 102.1 | 105.9 | 109.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -636.4 | -21.5 | 150.1 | 125.8 | 126.0 | 100.4 | 103.9 | 107.8 | 111.9 | 116.1 |
| WACC, % | 5.95 | 5.97 | 5.96 | 5.96 | 5.96 | 5.96 | 5.96 | 5.96 | 5.96 | 5.96 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 453.6 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 121 | |||||||||
| Terminal Value | 6,153 | |||||||||
| Present Terminal Value | 4,607 | |||||||||
| Enterprise Value | 5,060 | |||||||||
| Net Debt | -1,465 | |||||||||
| Equity Value | 6,526 | |||||||||
| Diluted Shares Outstanding, MM | 463 | |||||||||
| Equity Value Per Share | 14.10 |
What You Will Receive
- Authentic Vcanbio Data: Comprehensive financials – from revenue to EBIT – derived from actual and projected information.
- Complete Customization: Modify all key parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Adjustments: Automatic recalculations for assessing the effects of changes on Vcanbio’s fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth forecasts.
- Efficient and Precise: Avoid creating models from the ground up while ensuring accuracy and adaptability.
Key Features
- Pre-Loaded Data: Vcanbio Cell & Gene Engineering Corp., Ltd’s historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Instant Results: Watch Vcanbio’s intrinsic value update in real time.
- Clear Visual Outputs: Interactive dashboard charts showcase valuation results and key metrics.
- Built for Accuracy: A professional-grade tool designed for analysts, investors, and finance specialists.
How It Works
- 1. Download the Template: Access and open the Excel file containing Vcanbio Cell & Gene Engineering Corp., Ltd's (600645SS) preloaded data.
- 2. Adjust Key Assumptions: Modify essential inputs such as growth rates, WACC, and capital expenditures to fit your analysis.
- 3. Instant Results: The DCF model automatically calculates intrinsic value and NPV in real-time.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand potential valuation outcomes.
- 5. Present with Confidence: Share professional valuation insights to support your strategic decisions.
Why Choose This Calculator?
- Accurate Data: Up-to-date Vcanbio financials provide trustworthy valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you from building from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the industry.
- User-Friendly: Streamlined design and clear instructions make it accessible for users of all levels.
Who Can Benefit from This Product?
- Investors: Evaluate Vcanbio Cell & Gene Engineering Corp.'s (600645SS) market value before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation workflows and assess forecasts for better insights.
- Startup Founders: Understand the valuation methods of leading biotech companies like Vcanbio.
- Consultants: Provide accurate valuation reports to clients in the biotech sector.
- Students and Educators: Utilize current data to learn and teach valuation strategies effectively.
Contents of the Template
- Preloaded Vcanbio Data: Historical and estimated financial figures, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade spreadsheets for determining intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial reports for in-depth analysis.
- Key Ratios: Metrics on profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.